Prime Minister Moustafa Madbouly reviewed on Tuesday, June 2, 2026, a development plan for the Holding Company for Pharmaceuticals (HoldiPharma) and its subsidiaries. This came during a meeting attended by Deputy Prime Minister for Economic Affairs Hussein Eissa, Prime Minister's Assistant and CEO of the State-Owned Enterprises Unit Hashem el-Sayed, and Executive Managing Director of the HoldiPharma Ashraf el-Khouly.
Madbouly said the meeting comes as part of efforts to maximize the utilization of the Holding Company's capabilities in line with the state's vision to improve the management of public assets, enhance the economic returns of state-owned companies, and advance the pharmaceutical sector given its strategic importance for both domestic demand and exports.
The Prime Minister stressed that Egypt's pharmaceutical sector receives significant state support, with plans aimed at localizing pharmaceutical industries and transferring expertise and technology. He noted that Egypt possesses major national pharmaceutical entities and that the government remains committed to closely monitoring developments in this promising sector.
For his part, Hussein Eissa said the government is working seriously to implement clear restructuring plans for state-owned companies to improve institutional efficiency and support the country's economic objectives. Hashem el-Sayed highlighted that the HoldiPharma owns a number of highly distinguished subsidiaries.
He noted that a previous meeting had been held between the company's executive management and the State-Owned Enterprises Unit to develop a comprehensive vision for maximizing the value of this vital sector. During the meeting, Ashraf el-Khouly outlined the main features of the performance development plan for the Holding Company and its subsidiaries, whether wholly owned or listed on the Egyptian Exchange.
He explained that the company operates several specialized manufacturing facilities producing a wide range of pharmaceutical forms, including tablets, capsules, liquids, injections, medical solutions, inhalers, sterile eye drops, ointments and creams, as well as dental anesthetics.
The company also manufactures products on behalf of several global healthcare companies. El-Khouly said the company's strategic vision is to become an influential global healthcare hub by providing high-quality healthcare products and services, adopting advanced technologies, localizing research and development activities, and introducing innovative products.
He added that the company is implementing an integrated model that strengthens the unique brand identity of each subsidiary, enhances operational capabilities, optimizes resource utilization, rationalizes investments, and increases brand value.